Lerman C - Search Results

1

Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial.

Lerman C, Schnoll RA, Hawk LW Jr, Cinciripini P, George TP, Wileyto EP, Swan GE, Benowitz NL, Heitjan DF, Tyndale RF; PGRN-PNAT Research Group. Lerman C, et al. Lancet Respir Med. 2015 Feb;3(2):131-138. doi: 10.1016/S2213-2600(14)70294-2. Epub 2015 Jan 12. Lancet Respir Med. 2015. PMID: 25588294 Free PMC article. Clinical Trial.

2

Attention-Deficit Hyperactivity Disorder (ADHD) symptoms and smoking patterns among participants in a smoking-cessation program.

Lerman C, Audrain J, Tercyak K, Hawk LW Jr, Bush A, Crystal-Mansour S, Rose C, Niaura R, Epstein LH. Lerman C, et al. Nicotine Tob Res. 2001 Nov;3(4):353-9. doi: 10.1080/14622200110072156. Nicotine Tob Res. 2001. PMID: 11694203 Clinical Trial.

3

Mediating mechanisms for the impact of bupropion in smoking cessation treatment.

Lerman C, Roth D, Kaufmann V, Audrain J, Hawk L, Liu A, Niaura R, Epstein L. Lerman C, et al. Drug Alcohol Depend. 2002 Jul 1;67(2):219-23. doi: 10.1016/s0376-8716(02)00067-4. Drug Alcohol Depend. 2002. PMID: 12095672 Clinical Trial.

4

Non-replication of genetic association studies: is DAT all, folks?

Lerman C, Swan GE. Lerman C, et al. Nicotine Tob Res. 2002 Aug;4(3):247-9. doi: 10.1080/14622200210141220. Nicotine Tob Res. 2002. PMID: 12215232 No abstract available.

5

Pharmacogenetic investigation of smoking cessation treatment.

Lerman C, Shields PG, Wileyto EP, Audrain J, Pinto A, Hawk L, Krishnan S, Niaura R, Epstein L. Lerman C, et al. Pharmacogenetics. 2002 Nov;12(8):627-34. doi: 10.1097/00008571-200211000-00007. Pharmacogenetics. 2002. PMID: 12439223 Clinical Trial.

6

Dopamine transporter genotype as a risk factor for obesity in African-American smokers.

Epstein LH, Jaroni JL, Paluch RA, Leddy JJ, Vahue HE, Hawk L, Wileyto EP, Shields PG, Lerman C. Epstein LH, et al. Among authors: lerman c. Obes Res. 2002 Dec;10(12):1232-40. doi: 10.1038/oby.2002.168. Obes Res. 2002. PMID: 12490667 Free article.

7

Individual differences in nicotine intake per cigarette.

Patterson F, Benowitz N, Shields P, Kaufmann V, Jepson C, Wileyto P, Kucharski S, Lerman C. Patterson F, et al. Among authors: lerman c. Cancer Epidemiol Biomarkers Prev. 2003 May;12(5):468-71. Cancer Epidemiol Biomarkers Prev. 2003. PMID: 12750245

8

Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain.

Miksys S, Lerman C, Shields PG, Mash DC, Tyndale RF. Miksys S, et al. Among authors: lerman c. Neuropharmacology. 2003 Jul;45(1):122-32. doi: 10.1016/s0028-3908(03)00136-9. Neuropharmacology. 2003. PMID: 12814665

9

Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial.

Lerman C, Shields PG, Wileyto EP, Audrain J, Hawk LH Jr, Pinto A, Kucharski S, Krishnan S, Niaura R, Epstein LH. Lerman C, et al. Health Psychol. 2003 Sep;22(5):541-8. doi: 10.1037/0278-6133.22.5.541. Health Psychol. 2003. PMID: 14570538 Clinical Trial.

10

Subjective effects of an initial dose of nicotine nasal spray predict treatment outcome.

Kaufmann V, Jepson C, Rukstalis M, Perkins K, Audrain-McGovern J, Lerman C. Kaufmann V, et al. Among authors: lerman c. Psychopharmacology (Berl). 2004 Mar;172(3):271-6. doi: 10.1007/s00213-003-1659-8. Epub 2003 Nov 25. Psychopharmacology (Berl). 2004. PMID: 14647969 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

433 results

Search Page

Filters